Psilocybin and Successful Aging

Start with a slightly ridiculous question, because biology loves making respectable people ask ridiculous questions. Could a mushroom-derived compound, famous for making wallpaper breathe and adults say things like "I finally understand clouds," have anything useful to say about aging well? Not aging forever. Aging well: keeping enough emotional flexibility, purpose, curiosity, and neural adaptability to remain fully in the game.

That is the question behind UC Berkeley's PLASTICITY study, described by the Berkeley Center for the Science of Psychedelics. The study is enrolling adults ages 60 to 85 and using MRI scans before and after psilocybin to look for changes in brain structure, emotional function, awe, purpose, and other traits tied to healthy aging [1]. The broader question is whether a carefully supported psychedelic experience can shift systems that help older people stay resilient.

And now the bucket of cold water, because every interesting longevity claim needs one dumped on its head. This is not proof that psilocybin slows aging. As of the Berkeley interview, only two participants had completed all study visits, and the goal was to dose 20 participants by the end of 2026 [1]. Fascinating, yes. Clinically settled, no. Put down the confetti cannon.

The biological hook is neuroplasticity, a grand word for the brain's ability to change. Neurons strengthen connections, weaken them, grow new receiving points, prune old ones, and behave less like marble statues than like a city under renovation. This is wonderful, except when it is not. A plastic brain can learn a language or revise an old habit. It can also learn fear, addiction, rumination, and the mental ruts that make a person say, "Well, this is just how I am."

Aging complicates this renovation project. With age, many people show changes in synaptic connections and in regions such as the hippocampus and prefrontal cortex, areas involved in memory, emotional regulation, planning, and flexible thinking. These systems help you update your model of the world instead of living inside a cranky museum exhibit curated by your younger self.

This is where psychedelics became biologically interesting rather than merely culturally noisy. In a widely cited 2018 Cell Reports study, Ly and colleagues found that several psychedelic compounds promoted structural and functional neural plasticity in cultured cortical neurons and in animal models, including increased neurite growth and dendritic spine formation [2]. Dendritic spines are tiny protrusions where neurons receive many excitatory signals. More spines do not automatically mean a better brain; biology is not a home-improvement show where more shelving solves everything. But the finding supported the idea that psychedelics can amplify plasticity-related signaling.

The Berkeley study is trying to drag that idea out of the petri dish and the rodent cage, where many beautiful ideas have enjoyed brief celebrity careers before disappearing in humans. Participants receive a psilocybin dose between 1 and 30 mg and undergo MRI scans one week before, one week after, and one month after dosing [1]. The researchers are looking at structural plasticity, but also at depression, anxiety, stress, rumination, purpose in life, emotional regulation, and awe. Awe sounds soft, like something sold in a candle aisle, but psychologically it can make the world feel larger again.

That psychological side is not decorative fluff pasted onto the "real" biology. Successful aging is not just avoiding disease while the organs continue their reluctant committee work. It also involves meaning, relationships, emotional resilience, and engagement with life. A meta-analysis linked stronger purpose in life with lower all-cause mortality and fewer cardiovascular events [3]. That does not prove purpose single-handedly lengthens life, cape and clipboard in hand. But it argues against treating purpose as a cute accessory to health.

Psilocybin research already has evidence that it can affect some of these psychological domains, mostly in people with clinical conditions. In a 2020 randomized clinical trial, psilocybin-assisted therapy produced large reductions in major depressive disorder symptoms in a small group of adults [4]. A larger 2023 phase 2 trial found that a single 25 mg psilocybin dose with psychological support reduced depression scores more than niacin placebo at day 43 in adults with major depressive disorder [5]. These were not aging studies. Still, they help explain why researchers are interested in mood, meaning, and emotional flexibility rather than treating them as sentimental upholstery.

Cancer-related distress trials add another layer, and not a small one. In a randomized double-blind crossover trial, psilocybin produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer, with many participants reporting durable benefits at follow-up [6]. Again, this does not prove anything about healthy aging. But it suggests psilocybin can sometimes alter how people relate to illness, death, fear, and the story they tell about themselves. That is not immortality. It may be something more biologically modest and psychologically interesting: a temporary disruption of stuck patterns, followed by a chance to rebuild them better.

There is also a more directly biological aging thread, and here the science gets both exciting and easy to overinflate. In 2025, Kato and colleagues reported that psilocin, the active metabolite of psilocybin, extended the replicative lifespan of cultured human lung fibroblasts and that monthly psilocybin treatment improved survival over 10 months in aged female mice [7]. Humans, however, are not large mice with mortgages. Cell culture and mouse survival studies often fail to translate, sometimes heroically.

This is why the Berkeley work matters even if it is tiny. Older adults have barely been included in modern psychedelic trials. A 2024 systematic review found that among 1,400 participants across 36 psychedelic-assisted therapy studies, only 19 were age 65 or older, less than 1.4% of participants [8]. That is not a small gap. That is a canyon wearing a lab coat. Yet older adults are often the people facing depression, grief, chronic illness, cognitive worries, polypharmacy, cardiovascular disease, and existential distress.

A 2023 review focused on older adults made the same point with less theatrical arm-waving: psychedelics may have potential for conditions common in later life, but older adults with serious comorbidities have not been studied enough [9]. The authors also noted that psilocybin and MDMA can increase blood pressure and heart rate [9]. That detail matters. If you are 78, taking five medications, and your cardiologist has a folder with your name on it, a cardiovascular bump belongs to a different moral universe.

The safety issue is not just blood pressure. Psilocybin can produce intense changes in perception, emotion, time sense, and self-experience. In clinical research, participants are typically screened for psychosis risk, unstable medical conditions, high-risk medication interactions, and other factors. Government resources from NIDA and NCCIH emphasize that psilocybin is still being studied, can cause challenging psychological experiences, and remains a Schedule I controlled substance under federal law in the United States [10,11]. This is the unglamorous infrastructure behind the interesting brain scan: screening forms, trained support, dosing control, monitoring, follow-up. The clipboard is part of the magic trick.

And this is where the wellness world can become a blender with the lid off. A study using screened participants, trained facilitators, legal psilocybin, a known dose, MRI measurements, and follow-up visits is not the same as self-medicating because a podcast guest sounded confident. Dose, setting, support, expectations, medical history, and drug interactions all matter. For older adults, the margin for error can be narrower because of heart disease, hypertension, cognitive impairment, fall risk, and multiple medications.

The most interesting possibility is not that psilocybin becomes an "anti-aging pill," a phrase that should make everyone's skepticism glands secrete vigorously. The better hypothesis is subtler: psychedelics may help researchers understand how powerful experiences interact with brain plasticity. If psilocybin temporarily opens a window of increased plasticity, then what happens inside that window may matter enormously. Therapy, preparation, music, trust, integration, and meaning-making are not spa accessories. They may shape whether the mechanism produces something useful instead of just a memorable afternoon with the carpet.

So can psilocybin promote successful aging? The honest answer is: we do not know yet. The hypothesis is plausible enough to study because psilocybin affects serotonin 5-HT2A signaling, has preclinical evidence for plasticity, has clinical evidence for some mood and distress outcomes, and now has early cell and mouse aging data. But the human evidence in healthy older adults is just beginning. The correct scientific posture is not breathless enthusiasm or reflexive dismissal. It is forward lean plus brakes.

For now, the Berkeley PLASTICITY study is best understood as a careful first step into a neglected area. It asks whether older brains retain enough plasticity to respond meaningfully to psilocybin and whether the response includes changes that matter for aging well. That is a better question than whether psilocybin is a miracle longevity drug. Miracle is a word people use when they want biology to stop asking follow-up questions. The answer, if it comes, will need brain data, behavior, safety, durability, and the stubborn question: compared with what, for whom, and at what risk?

References

1. UC Berkeley Center for the Science of Psychedelics. Can Psilocybin Promote Successful Aging?. Published June 5, 2026. Accessed June 8, 2026.
2. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022. PMID: 29898390.
3. Cohen R, Bavishi C, Rozanski A. Purpose in Life and Its Relationship to All-Cause Mortality and Cardiovascular Events: A Meta-Analysis. Psychosom Med. 2016;78(2):122-133. doi:10.1097/PSY.0000000000000274. PMID: 26630073.
4. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285. PMID: 33146667.
5. Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843-853. doi:10.1001/jama.2023.14530. PMID: 37651119.
6. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. doi:10.1177/0269881116675513. PMID: 27909165.
7. Kato K, Kleinhenz JM, Shin YJ, Coarfa C, Zarrabi AJ, Hecker L. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. NPJ Aging. 2025;11(1):55. doi:10.1038/s41514-025-00244-x. PMID: 40628762.
8. Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, et al. Older adults in psychedelic-assisted therapy trials: A systematic review. J Psychopharmacol. 2024;38(1):33-48. doi:10.1177/02698811231215420. PMID: 38240068.
9. Johnston CB, Mangini M, Grob C, Anderson B. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. Am J Geriatr Psychiatry. 2023;31(1):44-53. doi:10.1016/j.jagp.2022.08.007. PMID: 36184377.
10. National Institute on Drug Abuse. Psilocybin (Magic Mushrooms). Accessed June 8, 2026.
11. National Center for Complementary and Integrative Health. Psilocybin for Mental Health and Addiction: What You Need To Know. Accessed June 8, 2026.